D-0277-2025 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0277-2025 was initiated by Rising Pharma Holding, Inc. on Mar 5, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: 1223 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 26, 2025
Initiation Date
Mar 5, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1223 bottles

Product description

Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC 57237-018-99

Reason for recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Distribution pattern

Nationwide in the USA.

Code information

Lot #: DTB23111A, Exp 8/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0277-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0277-2025. Report a data issue: hello@regdatalab.com.